Al Babtain Ibrahim, Alhadlaq Khalid H, Aljaafri Ziad A, Alhaqbani Abdullah, Al-Mutairi Abrar, AlZamel Heythem, Albedah Khaled, Alshalfan Raed, Alyami Rifan, Almalki Sami
General Surgery, Ministry of National Guard Health Affairs (MNGHA), Riyadh, SAU.
General Surgery, King Abdullah International Medical Research Center, Riyadh, SAU.
Cureus. 2024 Sep 13;16(9):e69334. doi: 10.7759/cureus.69334. eCollection 2024 Sep.
Introduction Hemorrhage following trauma is one of the leading causes of death worldwide. Venous thromboembolism (VTE) is a common complication of an increased coagulable state, and the risk of VTE following the administration of tranexamic acid (TXA), an antifibrinolytic agent, is still controversial. Our aim is to understand whether there is any association between the administration of TXA and the risk of VTE development. Methods A retrospective cohort study enrolled trauma patients presenting to a level 1 trauma center who received TXA at King Abdulaziz Medical City (KAMC), a tertiary hospital in Riyadh, Saudi Arabia, between 2016 and 2020. Variables included were patients' demographics, comorbidities, laboratory investigations, TXA's route of administration, date of administration, and dose. Finally, the development of VTE in the form of deep vein thrombosis (DVT) or PE and those who died were evaluated. Results A total of 361 adult trauma patients who received TXA were included in the study. Most were males (90.3%) with an average age of 33 years and had a normal BMI (43.3%). Nine patients (2.5%) developed DVT, one of whom died, and five patients (1.4%) developed PE, with no recorded deaths. Conclusion The risk of VTE following the administration of TXA remains controversial and yet to be clearly demonstrated. In this study, there was no significant association between TXA administration and the risk of developing VTE. More research with a larger sample size is needed to identify and recognize any significant risk factors for developing such a condition.
创伤后出血是全球主要的死亡原因之一。静脉血栓栓塞症（VTE）是高凝状态的常见并发症，而抗纤维蛋白溶解剂氨甲环酸（TXA）给药后发生VTE的风险仍存在争议。我们的目的是了解TXA给药与VTE发生风险之间是否存在关联。方法：一项回顾性队列研究纳入了2016年至2020年期间在沙特阿拉伯利雅得一家三级医院阿卜杜勒阿齐兹国王医疗城（KAMC）接受TXA治疗的一级创伤中心的创伤患者。纳入的变量包括患者的人口统计学特征、合并症、实验室检查、TXA的给药途径、给药日期和剂量。最后，评估深静脉血栓形成（DVT）或肺栓塞（PE）形式的VTE发生情况以及死亡患者情况。结果：共有361例接受TXA治疗的成年创伤患者纳入研究。大多数为男性（90.3%），平均年龄33岁，体重指数（BMI）正常（43.3%）。9例患者（2.5%）发生DVT，其中1例死亡；5例患者（1.4%）发生PE，无死亡记录。结论：TXA给药后发生VTE的风险仍存在争议，尚未得到明确证实。在本研究中，TXA给药与发生VTE的风险之间无显著关联。需要进行更大样本量的更多研究，以识别和认识发生这种情况的任何显著风险因素。
